Molecular biomarkers of cardiometabolic disease PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Molecular biomarkers of cardiometabolic disease PDF full book. Access full book title Molecular biomarkers of cardiometabolic disease by Mirjana Macvanin. Download full books in PDF and EPUB format.
Author: Mirjana Macvanin Publisher: Frontiers Media SA ISBN: 2832553494 Category : Medical Languages : en Pages : 100
Book Description
Cardiometabolic disease (CMD) represents the major cause of mortality, accounting for one-third of all global deaths, 75% of which occur in middle- and low-income countries. CMD encompasses a broad spectrum of conditions characterized by limited prediction, based mainly on classical risk factors due to a lack of accurate molecular CMD predictors. Thus, there is an urgent need for improved diagnostics solutions to support early intervention and improve outcomes. Early detection and adequate intervention are crucial to prevent CMD-associated complications, encouraging the quest for appropriate biomarkers with diverse applications ranging from risk assessment and screening to diagnosis and prognosis. Different circulating biomarkers for quantifying the CMD risk have been reported in the literature, such as C-reactive protein (CRP), leptin, and adiponectin. In addition, accumulating evidence in the literature points to the emergence of novel CMD biomarkers, such as cytokines, various metabolites, apelin, microRNAs, inflammasome molecules, and cardiac fibrosis markers. However, large meta-analyses have not sufficiently investigated and confirmed their biological roles in CMD diagnosis, prognosis, and/or potential reduction.
Author: Mirjana Macvanin Publisher: Frontiers Media SA ISBN: 2832553494 Category : Medical Languages : en Pages : 100
Book Description
Cardiometabolic disease (CMD) represents the major cause of mortality, accounting for one-third of all global deaths, 75% of which occur in middle- and low-income countries. CMD encompasses a broad spectrum of conditions characterized by limited prediction, based mainly on classical risk factors due to a lack of accurate molecular CMD predictors. Thus, there is an urgent need for improved diagnostics solutions to support early intervention and improve outcomes. Early detection and adequate intervention are crucial to prevent CMD-associated complications, encouraging the quest for appropriate biomarkers with diverse applications ranging from risk assessment and screening to diagnosis and prognosis. Different circulating biomarkers for quantifying the CMD risk have been reported in the literature, such as C-reactive protein (CRP), leptin, and adiponectin. In addition, accumulating evidence in the literature points to the emergence of novel CMD biomarkers, such as cytokines, various metabolites, apelin, microRNAs, inflammasome molecules, and cardiac fibrosis markers. However, large meta-analyses have not sufficiently investigated and confirmed their biological roles in CMD diagnosis, prognosis, and/or potential reduction.
Author: Pietro Scicchitano Publisher: MDPI ISBN: 3036508406 Category : Medical Languages : en Pages : 276
Book Description
ear Colleagues, The approach to diseases is facing novel frontiers: targeting gene and improving person-centered medicine able to easily and specifically detect early stages of pathologies. The present book includes the most futuristic approaches to the identification of cardiac diseases by means of the most recent discoveries in molecular and genetic diagnosis. The articles will give you the opportunity to think of cardiac diseases as adverse conditions which can be more easily detected by means of technologies and the research spirit of us, physicians dedicated to humans’ care. Please enjoy this reading.
Author: Michael Lichtenauer Publisher: MDPI ISBN: 3039438832 Category : Medical Languages : en Pages : 420
Book Description
Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers.
Author: Filipe Palavra Publisher: Springer ISBN: 3319160184 Category : Medical Languages : en Pages : 172
Book Description
This book discusses recent advances in the area of cardiometabolic risk biomarkers of chronic inflammatory and cardiovascular disorders. Tackling the topic in a systematic manner, the book starts with an introduction to cardiometabolic risk and its clinical relevance, comparing emergent and classical biomarkers. It then goes on to discuss cardiometabolic risk biomarkers in a range of diseases, including diabetes, ischemic stroke and neurodegenerative disorders. Biomarkers of Cardiometabolic Risk, Inflammation and Disease is aimed at doctors specializing in internal medicine, neurology, cardiology, rheumatology, nephrology or endocrinology and will also be of interest to GPs, trainee doctors and clinical and basic researchers working on cardiovascular and autoimmune disorders.
Author: Annabelle Rodriguez-Oquendo Publisher: Academic Press ISBN: 0128004746 Category : Science Languages : en Pages : 354
Book Description
Translational Cardiometabolic Genomic Medicine, edited by Dr. Annabelle Rodriguez-Oquendo, is an important resource to postgraduate (medical, dental and graduate) students, postdoctoral fellows, basic scientists, and physician scientists seeking to understand and expand their knowledge base in the field of genomic medicine as it is applied to cardiometabolic diseases. This handbook integrates cutting-edge experimental approaches such as chromatin immunoprecipitation paired end tagging (CHIA-PET), to population studies such as the Multi-Ethnic Study of Atherosclerosis. It encompasses a range of book chapters that highlight bioinformatic approaches to better understanding functionality of the noncoding regions of the human genome to the use of molecular diagnostic testing in predicting increased risk of cardiovascular diseases. Where applicable, this reference also includes chapters related to therapeutic options specifically aligned to molecular targets. Provides comprehensive research on translational genomic medicine Explains state-of-the-art genome editing for stem cells and mouse models with significant relevance to human cardiometabolic disease Includes discussions on the functional effects of single nucleotide polymorphisms and cardiometabolic diseases, stratified by sex and race Encompasses a range of book chapters that highlight bioinformatic approaches to better understanding functionality of the noncoding regions of the human genome
Author: Dimitris Tousoulis Publisher: CRC Press ISBN: 1466587148 Category : Medical Languages : en Pages : 452
Book Description
The establishment of precise and reliable biomarker tests for the early stages of cardiovascular disease is of great importance and can be the cornerstone in the prevention of future cardiovascular disease (CVD). Furthermore, some biomarkers may provide important information concerning the pathogenesis of CVD or appear to be useful in risk stratification, in CVD diagnosis, or in monitoring therapy; many others may be risk factors themselves, representing therefore potential targets of therapy. The ideal biomarker should have the following characteristics: highly sensitive, specific, reliable, accessible, standardized, dependable, cost effective, and easily interpretable by clinicians. The present book focuses on the presentation and evaluation of the most promising classical and novel biochemical markers used in CVD (coronary artery disease, hypertension, heart failure, hyperlipidemia, peripheral arterial disease). The underlying pathophysiological characteristics of each biomarker, as well as potential clinical implications in daily practice are reviewed in this book.
Author: Vijay Nambi Publisher: Elsevier Health Sciences ISBN: 0323548369 Category : Medical Languages : en Pages : 400
Book Description
Get a quick, expert overview of the ways in which biomarkers can be used to assess and guide the management of cardiovascular disease in the clinical setting. This concise, clinically-focused resource by Dr. Vijay Nambi consolidates today’s available information on this rapidly changing topic into one convenient resource, making it an ideal, easy-to-digest reference for cardiology practitioners, fellows, and residents. Covers lab standards and statistical interpretation of biomarkers with a clinical focus. Discusses relevant conditions such as hypertension and diabetes as key markers of injury and prognosis. Includes current information on biomarkers to assess and guide the management of heart failure, acute coronary syndrome, chest pain, shortness of breath, and more. Concludes the book with a timely chapter on how biomarkers may guide cardiologists in the future.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309157277 Category : Medical Languages : en Pages : 335
Book Description
Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process.
Author: Victor R. Preedy Publisher: Springer ISBN: 9789400777415 Category : Medical Languages : en Pages : 800
Book Description
In the past decade there has been a major sea change in the way disease is diagnosed and investigated due to the advent of high throughput technologies, such as microarrays, lab on a chip, proteomics, genomics, lipomics, metabolomics etc. These advances have enabled the discovery of new and novel markers of disease relating to autoimmune disorders, cancers, endocrine diseases, genetic disorders, sensory damage, intestinal diseases etc. In many instances these developments have gone hand in hand with the discovery of biomarkers elucidated via traditional or conventional methods, such as histopathology or clinical biochemistry. Together with microprocessor-based data analysis, advanced statistics and bioinformatics these markers have been used to identify individuals with active disease or pathology as well as those who are refractory or have distinguishing pathologies. New analytical methods that have been used to identify markers of disease and is suggested that there may be as many as 40 different platforms. Unfortunately techniques and methods have not been readily transferable to other disease states and sometimes diagnosis still relies on single analytes rather than a cohort of markers. There is thus a demand for a comprehensive and focused evidenced-based text and scientific literature that addresses these issues. Hence the formulation of Biomarkers in Disease. The series covers a wide number of areas including for example, nutrition, cancer, endocrinology, cardiology, addictions, immunology, birth defects, genetics, and so on. The chapters are written by national or international experts and specialists.
Author: Mirjana Macvanin
Author: Mirjana Macvanin
Author: Pietro Scicchitano
Author: Yuli Huang
Author: Michael Lichtenauer
Author: Filipe Palavra
Author: Annabelle Rodriguez-Oquendo
Author: Dimitris Tousoulis
Author: Vijay Nambi
Author: Institute of Medicine
Author: Victor R. Preedy